The better-than-expected EPS could be seen positively by investors, indicating potential operational efficiency or cost management improvements. However, the miss on sales estimates could raise concerns about revenue growth and market demand for Profound Medical's products. The mixed results make the short-term stock price direction uncertain, hence a neutral score.